Core Viewpoint - The recent statements from Purity and New Oxygen highlight a significant dispute regarding the use and distribution of Purity's products, with both companies asserting their positions on product safety and legitimacy [1][2][3] Group 1: Purity's Statement - Purity has released a formal statement identifying several unauthorized medical institutions, including over 40 New Oxygen stores, which are now on a "never cooperate" blacklist [1] - The company emphasizes that the listed institutions did not procure products through official channels, thus denying any responsibility for the authenticity of the products used by these institutions [1] - Purity asserts that its products should only be used in officially approved medical institutions by qualified professionals who have received proper training [1] Group 2: New Oxygen's Response - New Oxygen has issued a statement refuting Purity's claims, asserting that all products used in their clinics are sourced from legally qualified suppliers with complete procurement documentation [2] - The company highlights that its clinics are legally approved medical institutions, and the doctors operate in compliance with medical laws and regulations [2] - New Oxygen condemns the dissemination of misleading information that could harm its reputation and consumer trust, stating that such actions disrupt fair market competition [3] Group 3: Legal Actions and Consumer Rights - New Oxygen has taken legal steps by commissioning a law firm to demand the removal of Purity's statements, seeking to protect its reputation and consumer rights [3] - The company emphasizes the importance of professional support from upstream manufacturers, arguing that it should not be manipulated for market control or to impose barriers on medical institutions [3]

Core Viewpoint - The National Cybersecurity Notification Center reported that 40 mobile applications were found to illegally collect and use personal information, highlighting concerns over data privacy and compliance in the tech industry [1] Company Summary - The application "e看牙" (version 4.37.2) was identified as one of the violators, collecting personal information without user consent [1] - The operator of "e看牙" is Shanghai Lingjian Information Technology Co., Ltd., established in 2015 and primarily engaged in software and information technology services [1] - The registered capital of Shanghai Lingjian Information Technology Co., Ltd. is 25.032413 million RMB, with a paid-in capital of 21.8034712 million RMB [1] - The largest shareholder of Shanghai Lingjian Information Technology Co., Ltd. is Beijing Xinyang Souyang Investment Management Co., Ltd., holding an 11.107% stake [1] - Beijing Xinyang Souyang Investment Management Co., Ltd. is a wholly-owned subsidiary of Beijing Xinyang Technology Co., Ltd. [1]

Group 1 - The report highlights that Xingfa Group's Q3 net profit attributable to shareholders increased by 16.17% year-on-year, driven by rising prices of glyphosate and other products, with a total revenue of 91.61 billion yuan in Q3 2025, reflecting a 5.96% year-on-year growth [3][4][9] - The report indicates that the average price of glyphosate reached 26,530 yuan per ton in Q3 2025, up 5% year-on-year, while the average price of phosphate rock remained high at 1,020 yuan per ton [4][6] - The acquisition of a 50% stake in Qiaogou Mining is expected to enhance the company's phosphate resource advantages, increasing its phosphate resource reserves from 3.95 billion tons to 5.80 billion tons [7][8] Group 2 - The report notes that Leap Motor's Q3 revenue surged by 97.3% year-on-year to 194.5 billion yuan, with a gross margin of 14.5%, marking a significant improvement [11][12] - The company is expanding its product lineup with the introduction of the D19 flagship model and the upcoming A10 model, which is expected to enhance its market position [13] - Leap Motor's export volume reached 17,000 units in Q3 2025, leading among new car manufacturers, and the company plans to accelerate its global localization strategy [14] Group 3 - Geely Automobile reported a Q3 revenue of 891.9 billion yuan, a 27% year-on-year increase, with a net profit of 38.2 billion yuan, reflecting a 59% year-on-year growth [16][17] - The company has adjusted its annual sales target to 3 million units, with significant contributions from its Galaxy series of vehicles [18] - Geely's export volume reached 112,000 units in Q3 2025, indicating strong overseas demand and competitive positioning [19] Group 4 - The report on Lianqi Technology emphasizes its leadership in memory interconnect chips, with a revenue of 6.33 billion yuan in the first three quarters of 2025, a 57.83% year-on-year increase [21][22] - The global AI server shipment is projected to grow significantly, with Lianqi expected to capture a 36.8% market share in the memory interconnect chip market by 2024 [22][23] - The company has launched new products based on CXL technology, which are anticipated to drive future growth [23] Group 5 - The report indicates that Xinyang's Q3 revenue reached 387 million yuan, with a significant increase in beauty treatment service revenue, which grew by 304.6% year-on-year [25][26] - The company plans to expand its offline medical beauty stores to 50 by the end of the year, enhancing its market presence [25] - Despite a net loss in Q3, the company expects profitability improvements in Q4 due to seasonal demand recovery [26] Group 6 - Trip.com Group reported a Q3 net operating revenue of 18.3 billion yuan, a 16% year-on-year increase, with a net profit of 19.9 billion yuan, reflecting a 194% year-on-year growth [29][30] - The company is benefiting from resilient domestic travel demand and strong growth in international business, particularly in cross-border travel [30][31] - The report anticipates continued growth in the global OTA business, with significant contributions from the Asia-Pacific region [31][32] Group 7 - Pinduoduo's Q3 revenue reached 108.3 billion yuan, a 9% year-on-year increase, with a Non-GAAP net profit of 31.4 billion yuan, up 14% year-on-year [39][40] - The report highlights a slowdown in advertising revenue growth, while transaction commission revenue continues to show steady performance [41] - The company is focusing on long-term value creation through increased investments in merchant support and platform development [42]

Investment Rating - The report maintains an "Outperform" rating for the company, indicating an expectation of relative performance exceeding the benchmark index by over 10% in the next 12-18 months [1]. Core Insights - The medical aesthetics industry is experiencing a continuous expansion of its consumer base, currently undergoing a reshuffling phase where a few chain brands are expected to capture a larger market share [4]. - The company has a clear development plan for its light medical aesthetics chain, with specific strategies being formulated to establish itself as an industry leader in the foreseeable future [1]. - The stock price of the company is currently undervalued at $3.16, corresponding to a price-to-earnings ratio of only 12 times for its 50 mature stores, with expectations of significant revenue growth [2]. Summary by Sections Industry Trends - The consumer base for medical aesthetics continues to grow, and the industry is in a reshuffling phase, with larger chain brands likely to dominate the market [4]. Company Expansion Plans - The company plans to open over 35 new stores in the upcoming year, primarily focusing on direct-operated stores in major cities like Beijing, Shanghai, Guangzhou, and Shenzhen [4]. - There are already several stores in the opening process, indicating that the company is on track to meet its expansion goals without significant pressure [4]. Store Performance - The average store size is 400 square meters, with mature stores showing excellent profit margins and net profit rates, suggesting strong long-term performance [4]. Competitive Landscape - The current competition is intense, with many standalone institutions lacking advantages in branding, medical teams, supply chains, and location, making it difficult for them to compete with established chains [4]. Product Pipeline - The company is set to launch multiple products next year, including water light injections, youth needles, silk collagen, and extracellular matrix gels, which are expected to enhance its market position [4].

Industry Trends - The medical beauty industry continues to expand, with a consolidation phase where a few chain brands will capture a larger market share[4] - The distribution of industry profits may change as upstream manufacturers undergo similar consolidation, enhancing the pricing power of large downstream institutions[4] Company Performance and Strategy - The current stock price of New Oxygen (SY US) is $3.16, which is considered undervalued, corresponding to a P/E ratio of only 12 times for its 50 mature stores[2] - Management is confident in opening at least 35 new stores in FY2026, primarily focusing on direct-operated stores in major cities like Beijing, Shanghai, Guangzhou, and Shenzhen[4] - In Q3, 20 stores achieved monthly profitability, with mature stores averaging monthly revenue exceeding RMB 3 million[2] Financial Projections - The target price for New Oxygen is set at $10.00 per ADR, based on a Sum-of-the-Parts (SoTP) valuation method, which includes various business segments with different P/E ratios[2] - The retail business is projected to have a steady operating profit margin of 20%, while the medical beauty chain is expected to achieve a 15% steady operating profit margin[2] Competitive Landscape - The competition is intensifying, with most standalone institutions lacking advantages in branding, medical teams, supply chains, and location, making it difficult to compete with chains[4] - New Oxygen is not overly concerned about traditional institutions due to the significant differences in cost structures and operational dimensions[4]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was RMB 387 million, up 305% year-over-year and approximately 8% above the high end of guidance [3][17] - Net loss attributable to So-Young increased to RMB 64.3 million compared to a net income of RMB 20.3 million in the same period last year [20] - Non-GAAP net loss was RMB 61.6 million compared to a non-GAAP net income of RMB 22.2 million during the same period of 2024 [20] Business Line Data and Key Metrics Changes - Revenue from the aesthetic center business reached RMB 184 million, up 305% year-over-year [3][17] - Information and reservation services revenues were RMB 117.2 million, down 34.5% year-over-year [17] - Revenues from sales of medical products and maintenance services were RMB 67 million, down 25% year-over-year [17] Market Data and Key Metrics Changes - Total number of active users of So-Young Clinic exceeded 130,000, with verified treatment visits surpassing 89,800, up 33% quarter-to-quarter [6] - The proportion of new customers acquired via referrals rose to 46% [7] - Cumulative service visits exceeded 600,000, ranking first among mass-market chain brands in China [4] Company Strategy and Development Direction - The company aims to expand its aesthetic center network to 1,000 centers, focusing on core cities and commercial hubs [15] - A disciplined approach to expansion will be maintained, emphasizing operational excellence and cost optimization [21] - The company is enhancing its membership system to increase user retention and customer lifetime value [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in stabilizing revenues from non-aesthetic center businesses in Q4 [3] - The company is focused on improving operational efficiency and service quality, with 20 centers achieving profitability in Q3 [6] - Future profitability is expected to improve as the operating model matures and customer acquisition costs are optimized [52][54] Other Important Information - The company upgraded its quality control framework, implementing a six-tier compliance system [11][44] - The launch of Miracle PLLA 3.0 was highlighted as a significant product upgrade, with strong pre-sale performance [9][36] - The company received recognition from mainstream media for its disciplined operations and compliance management [12] Q&A Session Summary Question: Plans for next year's clinic openings - Management plans to open no less than 35 new centers next year, focusing on first-tier cities and systematically establishing a presence in second-tier cities [25] Question: Membership system operations - The membership system is tiered, with core members contributing significantly to revenue and repeat purchase rates [30][32] Question: Performance of Miracle PLLA 3.0 - Miracle PLLA 3.0 has received high attention, with the first batch sold out quickly, and plans for further market penetration are in place [36][37] Question: Ensuring safety and compliance - A six-pillar compliance framework has been established to ensure safety and quality across all centers [43][46] Question: Improving profitability of the aesthetic center business - Management believes profitability will improve as the user base expands and operational efficiencies are realized [52][54]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was RMB 387 million, up 305% year-over-year and approximately 8% above the high end of guidance [3][17] - Net loss attributable to So-Young increased to RMB 64.3 million compared to a net income of RMB 20.3 million in the same period last year [21] - Non-GAAP net loss was RMB 61.6 million compared to a non-GAAP net income of RMB 22.2 million during the same period of 2024 [21] Business Line Data and Key Metrics Changes - Revenue from the aesthetic center business reached RMB 184 million, up 305% year-over-year and 26% quarter-to-quarter [3][5] - Information and reservation services revenues were RMB 117.2 million, down 34.5% year-over-year [17] - Revenues from sales of medical products and maintenance services were RMB 67 million, down 25% year-over-year [17] Market Data and Key Metrics Changes - Total number of active users of So-Young Clinic exceeded 130,000, with verified treatment visits surpassing 89,800, up 33% quarter-to-quarter and 280% year-over-year [6][8] - The proportion of new customers acquired via referrals rose to 46% [7] - Customer satisfaction score remained high at 4.99 out of 5 [8] Company Strategy and Development Direction - The company aims to reach 1,000 centers in the long term, focusing on disciplined expansion in core cities and commercial hubs [15][22] - The strategy includes enhancing standardized and digital management to improve service delivery and user experience [15] - The company is shifting from marketing-driven to trust-driven operations, emphasizing transparency and compliance [12] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in stabilizing revenues from non-aesthetic center businesses in Q4 [3] - The outlook for Q4 2025 expects aesthetic treatment services revenues to be between RMB 216 million and RMB 226 million, representing a 165.8%-178.1% increase from the same period in 2024 [22] - The company plans to continue optimizing customer acquisition costs and enhancing profitability as the operating model matures [50][52] Other Important Information - The company upgraded its quality control framework, implementing a six-tier compliance system to ensure service quality [10][44] - The launch of Miracle PLLA 3.0 was successful, with over 1,300 orders completed within two days [9][36] - The company completed 55 center inspections and emergency drills in Q3 [10] Q&A Session Summary Question: Plans for next year's clinic openings - Management plans to open no less than 35 new centers next year, focusing on first-tier cities and gradually expanding into second-tier cities [26][27] Question: Membership system operations - The membership system is tiered, with core members contributing significantly to revenue and having a high repurchase rate [30][31] Question: Miracle PLLA 3.0 performance - Miracle PLLA 3.0 has received high attention, with a successful launch and strong market feedback [36][37] Question: Ensuring safety and compliance - The company has established a six-pillar compliance framework and conducts regular inspections to maintain high service standards [43][44] Question: Improving profitability of the aesthetic center business - Management believes profitability will improve as the user base expands and operational efficiencies are realized [50][52]

Core Insights - New Oxygen (SY.US) reported Q3 revenue of $54.3 million, a 4.0% year-over-year increase, exceeding market expectations; the company recorded a loss of $0.09 per share [1] - Revenue from beauty treatment services surged 304.6% year-over-year to RMB 183.6 million ($25.8 million), surpassing guidance [1] - The number of verified treatment visits at brand beauty centers exceeded 89,800 in Q3, compared to approximately 23,600 in the same period last year [1] Financial Performance - Active users visiting brand beauty centers over the 12 months ending September 30, 2025, exceeded 130,000, up from about 30,300 year-over-year [1] - The number of core users increased by over 10,000 in the quarter, achieving a 40% quarter-over-quarter growth; these core members contributed 88% of beauty care service revenue with a quarterly repurchase rate of approximately 70% [1] - As of September 30, 2025, total cash and cash equivalents, restricted cash, time deposits, and short-term investments amounted to RMB 942.8 million (approximately $132.4 million), down from RMB 1.2532 billion as of December 31, 2024, primarily due to increased investments in brand beauty centers [1] Future Outlook - For Q4 2025, New Oxygen expects revenue from beauty care services to be between RMB 216 million (approximately $30.3 million) and RMB 226 million (approximately $31.7 million), representing a year-over-year growth of 165.8% to 178.1% [2]

Exhibit 99.1 So-Young Reports Unaudited Third Quarter 2025 Financial Results BEIJING, China, November 17, 2025 — So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Third Quarter 2025 Operational Highlights This press release contains trans ...

Core Insights - So-Young International Inc. reported its unaudited financial results for Q3 2025, highlighting significant growth in aesthetic treatment services and an increase in operational efficiency despite a net loss [1][7][9]. Financial Highlights - Total revenues for Q3 2025 were RMB 386.7 million (US$ 54.3 million), a 4.0% increase from RMB 371.8 million in Q3 2024 [10]. - Aesthetic treatment services revenues surged to RMB 183.6 million (US$ 25.8 million), marking a 304.6% increase from RMB 45.4 million in the same period of 2024 [14]. - The net loss attributable to So-Young was RMB 64.3 million (US$ 9.0 million), compared to a net income of RMB 20.3 million in Q3 2024 [19]. - Non-GAAP net loss was RMB 61.6 million (US$ 8.7 million), contrasting with a non-GAAP net income of RMB 22.2 million in Q3 2024 [20]. Operational Highlights - The number of verified treatment visits to branded aesthetic centers exceeded 89,800, up from approximately 23,600 in Q3 2024 [7]. - Active users reached over 130,000, a significant increase from approximately 30,300 users in the same period last year [7]. - The company operated 39 fully functional branded aesthetic centers across ten major cities, with 20 centers achieving profitability in Q3 2025 [7][9]. Cost and Expenses - Cost of revenues increased to RMB 203.8 million (US$ 28.6 million), a 43.4% rise from RMB 142.2 million in Q3 2024 [13]. - Operating expenses totaled RMB 255.6 million (US$ 35.9 million), reflecting a 13.6% increase from RMB 225.0 million in the same quarter of 2024 [17]. Business Outlook - For Q4 2025, So-Young anticipates aesthetic treatment services revenues to be between RMB 216.0 million (US$ 30.3 million) and RMB 226.0 million (US$ 31.7 million), representing a projected increase of 165.8% to 178.1% compared to Q4 2024 [24].